| PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation K Ezzat, S El Andaloussi, EM Zaghloul, T Lehto, S Lindberg, PMD Moreno, ... Nucleic acids research 39 (12), 5284-5298, 2011 | 288 | 2011 |
| Human induced pluripotent stem cell (hiPSC)-derived cells to assess drug cardiotoxicity: opportunities and problems T Magdy, AJT Schuldt, JC Wu, D Bernstein, PW Burridge Annual review of pharmacology and toxicology 58, 83-103, 2018 | 109 | 2018 |
| Negligible-cost and weekend-free chemically defined human iPSC culture HH Kuo, X Gao, JM DeKeyser, KA Fetterman, EA Pinheiro, CJ Weddle, ... Stem Cell Reports 14 (2), 256-270, 2020 | 108 | 2020 |
| Genetics, epigenetics, and regulation of drug‐metabolizing cytochrome P450 enzymes UM Zanger, K Klein, M Thomas, JK Rieger, R Tremmel, BA Kandel, ... Clinical Pharmacology & Therapeutics 95 (3), 258-261, 2014 | 108 | 2014 |
| Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? T Magdy, BT Burmeister, PW Burridge Pharmacology & therapeutics 168, 113-125, 2016 | 82 | 2016 |
| Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions K Ezzat, EM Zaghloul, SEL Andaloussi, T Lehto, R El-Sayed, T Magdy, ... Journal of controlled release 162 (1), 1-8, 2012 | 65 | 2012 |
| Role of ABC transporters in fluoropyrimidine-based chemotherapy response AT Nies, T Magdy, M Schwab, UM Zanger Advances in cancer research 125, 217-243, 2015 | 58 | 2015 |
| Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity T Magdy, M Jouni, HH Kuo, CJ Weddle, D Lyra-Leite, H Fonoudi, ... Circulation 145 (4), 279-294, 2022 | 54 | 2022 |
| RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy T Magdy, Z Jiang, M Jouni, H Fonoudi, D Lyra-Leite, G Jung, ... Cell stem cell 28 (12), 2076-2089. e7, 2021 | 50 | 2021 |
| Targeting OCT3 attenuates doxorubicin-induced cardiac injury KM Huang, M Zavorka Thomas, T Magdy, ED Eisenmann, ME Uddin, ... Proceedings of the National Academy of Sciences 118 (5), e2020168118, 2021 | 47 | 2021 |
| Association of GSTM1 null variant with anthracycline‐related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report P Singh, X Wang, L Hageman, Y Chen, T Magdy, W Landier, JP Ginsberg, ... Cancer 126 (17), 4051-4058, 2020 | 26 | 2020 |
| ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression T Magdy, R Arlanov, S Winter, T Lang, K Klein, Y Toyoda, T Ishikawa, ... Pharmacogenomics 14 (12), 1433-1448, 2013 | 16 | 2013 |
| Human in vitro models for assessing the genomic basis of chemotherapy-induced cardiovascular toxicity EA Pinheiro, T Magdy, PW Burridge Journal of cardiovascular translational research 13 (3), 377-389, 2020 | 13 | 2020 |
| The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity T Magdy, PW Burridge Pharmacogenomics 19 (2), 79-82, 2018 | 13 | 2018 |
| Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease T Magdy, P Burridge Cell stem Cell 24 (2), 203-205, 2019 | 8 | 2019 |
| Precise and cost-effective nanopore sequencing for post-GWAS fine-mapping and causal variant identification T Magdy, HH Kuo, PW Burridge Iscience 23 (4), 2020 | 7 | 2020 |
| Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity T Magdy, PW Burridge Pharmacogenomics 22 (1), 41-54, 2021 | 5 | 2021 |
| Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy P Singh, L Zhou, DA Shah, RB Cejas, DK Crossman, M Jouni, T Magdy, ... Scientific reports 13 (1), 12683, 2023 | 3 | 2023 |
| Brief research reports in pharmacogenetics and pharmacogenomics: 2022 F Sessa, T Magdy, C Sukasem, GP Patrinos Frontiers in Pharmacology 14, 1172265, 2023 | 2 | 2023 |
| Functional validation of doxorubicin-induced cardiotoxicity-related genes H Fonoudi, M Jouni, RB Cejas, T Magdy, M Blancard, N Ge, DA Shah, ... Cardio Oncology 6 (1), 38-50, 2024 | 1 | 2024 |
